WESTLAKE VILLAGE, Calif. -
Acquisition transfers a premium 850 MW Japanese BESS development portfolio and an experienced local development team from BayWa r.e. AG, one of the world’s leading renewable energy independent power producers

Portfolio includes 350 MW of near term, advanced-stage projects expected to reach NTP in 2H 2027, with COD beginning in mid-2028, plus 500 MW of early-stage projects supporting long-term growth and development

Japanese projects are expected to be designed with three-hour duration, generating higher EBITDA per MW than typical shorter-duration BESS projects in Texas.

Transaction brings Energy Vault’s global owned asset portfolio for near term projects underway to 1.1 GW, contributing to $180M+ in expected annual recurring EBITDA as the projects come online

(BUSINESS WIRE)--Energy Vault Holdings, Inc. (NYSE: NRGV) (“Energy Vault” or the “Company”), a global leader in sustainable grid-scale energy storage and AI compute inf ... Read more »

HOUSTON - Thursday, 28. May 2026 AETOSWire

Agreement supports Vår Energi’s ambition to reduce time to first oil, building on multi-discipline, collaborative well planning workflows that reduce cycle times from months to days

(BUSINESS WIRE)--Global energy technology company SLB (NYSE: SLB) today announced an expanded collaboration with Vår Energi to scale well planning and integrated field development planning across its Norwegian Continental Shelf operations. With collaborative well planning already reducing cycle times from months to days and integrated field development planning expected to support similar benefits, the expanded deployment is designed to support faster, more consistent decision-making as operators work to sustain production from mature offshore assets while managing increasing development complexity.

As part of the expanded collaboration, Vår Energi is deploying the Delfi™ digital platform to connect exploration, subsurface evaluation, well ... Read more »

SAN FRANCISCO - Thursday, 28. May 2026


RLS-1496 is an investigational, first-in-class, disease-modifying, selective glutathione peroxidase 4 (GPX4) modulator that targets pathologic senescent and other stressed, aging cells that drive chronic, age-dependent diseases, such as AK, and represents a novel drug category — Adaptive SenoTherapeutics
In recognition of May as Skin Cancer Awareness Month, Rubedo is calling attention to the myths and facts surrounding AKs — and to the urgent need for a new generation of treatments that are effective without the side-effect burden of today's options




(BUSINESS WIRE)--Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a Phase 1b/2a study of RLS-1496 in patients with actinic keratosis (AK), a common age-related condition resulting in precancerous skin lesions, that is most co ... Read more »

TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEA

Oral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1%

(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago. The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA).

Dr. Sun Young Rha, Professor of Medical Onc ... Read more »